Insider Selling: Candel Therapeutics, Inc. (NASDAQ:CADL) Insider Sells 13,673 Shares of Stock

Candel Therapeutics, Inc. (NASDAQ:CADL) insider Francesca Barone sold 13,673 shares of the stock in a transaction that occurred on Wednesday, January 8th. The shares were sold at an average price of $8.22, for a total value of $112,392.06. Following the transaction, the insider now directly owns 124,207 shares of the company’s stock, valued at $1,020,981.54. This trade represents a 9.92 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Candel Therapeutics Stock Performance

Shares of Candel Therapeutics stock traded down $0.55 during trading on Friday, hitting $8.18. 999,637 shares of the stock were exchanged, compared to its average volume of 1,379,625. Candel Therapeutics, Inc. has a 1-year low of $1.16 and a 1-year high of $14.60. The stock has a market capitalization of $265.65 million, a price-to-earnings ratio of -4.73 and a beta of -1.20. The company has a fifty day moving average price of $6.37 and a 200-day moving average price of $6.22. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 1.66.

Institutional Trading of Candel Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Point72 DIFC Ltd acquired a new position in shares of Candel Therapeutics during the 2nd quarter worth approximately $31,000. FMR LLC acquired a new position in shares of Candel Therapeutics in the third quarter valued at $46,000. MetLife Investment Management LLC bought a new position in shares of Candel Therapeutics in the third quarter valued at about $87,000. Atom Investors LP acquired a new stake in shares of Candel Therapeutics during the 3rd quarter worth about $103,000. Finally, State Street Corp grew its stake in Candel Therapeutics by 4.1% in the 3rd quarter. State Street Corp now owns 492,005 shares of the company’s stock valued at $3,410,000 after buying an additional 19,207 shares during the last quarter. Institutional investors own 13.93% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $19.00 target price (up from $11.00) on shares of Candel Therapeutics in a research note on Wednesday, December 18th.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.